You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《全日總結》恆指升329點 渣打績後揚一成 內銀及科網股發力
港股在期指結算日造好。恆指高開172點,其後升幅曾擴大至340點一度高見20,286點,全日升329點或1.65%,收20,276點;國指升132點或1.95%,收6,918點;恆生科技指數升85點或2.15%,收4,066點。大市全日成交總額降至1,057.54億元。滬、深港通南下交易因五一假期暫停,將於5月5日重開。 渣打(02888.HK)首季業績及資本表現勝預期,該股升10.4%報52.9元。匯控(00005.HK)升1.6%報48.85元,港交所(00388.HK)升1.4%報325.8元,友邦(01299.HK)升1.8%報77.9元。 中資金融股反彈,招行(03968.HK)升5.7%報46.95元,建行(00939.HK)、工行(01398.HK)、農行(01288.HK)及中行(03988.HK)各升2.1%至2.6%。中國太平(00966.HK)、新華保險(01336.HK)及財險(02328.HK)各升3.5%至4.3%。中國平安(02318.HK)及太保(02601.HK)各升2%及2.6%。 科技股方面,騰訊(00700.HK)升1.5%報339.8元,阿裏巴巴(09988.HK)升4.4%報88.25元,京東(09618.HK)升4.5%報229.6元,百度(09888.HK)升4.1%報118.4元,嗶哩嗶哩(09626.HK)及衆安在線(06060.HK)各升6.2%及5.3%,金山軟件(03888.HK)升7%。金蝶(00268.HK)、攜程(09961.HK)及明源雲(00909.HK)各升3.6%至4.1%。 醫藥股造好,國藥集團中國生物指Omicron新冠滅活疫苗臨牀研究需三至四個月完成,國藥(01099.HK)揚5.4%。石藥(01093.HK)及中生製藥(01177.HK)各升3.6%及3.8%,白雲山(00874.HK)及信達生物(01801.HK)各升4.4%及6.2%。 內需及消費股普遍上升,萬洲(00288.HK)獲大摩唱好,股價升4.1%。煤炭股急漲,神華(01088.HK)及中煤能源(01898.HK)各升8.8%及10.2%,兗礦能源(01171.HK)升5.6%。鋼鐵股馬鋼(00323.HK)升3%。基建股續受捧,中鐵建(01186.HK)升2.8%,中國中鐵(00390.HK)及中交建(01800.HK)各升4.8%及4.1%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account